Projektbeschreibung
Neuartige Behandlung von arzneimittelresistenten bakteriellen Lungeninfektionen
Die zunehmende Resistenz gegen viele Antibiotika und das Auftreten multiresistenter Bakterien erfordert die Entwicklung alternativer antibakterieller Therapien. Gegenwärtig ist die bakterielle Arzneimittelresistenz die Hauptursache für Morbidität und Mortalität bei Patienten mit Mukoviszidose und im Krankenhaus erworbenen Lungeninfektionen. Im Rahmen des EU-finanzierten Projekts wird eine neue Behandlung gegen bakterielle Lungeninfektionen entwickelt. Dazu wird das Team inhalierbare Lichtquellen nutzen, die bakterielle endogene Photosensibilisatoren (Porphyrine) anregen und die Bakterien durch den photodynamischen Effekt (lokale Produktion von reaktivem zytotoxischem Sauerstoff) abtöten. Die Behandlung wird für das Wirtsgewebe sicher und wirksam gegen arzneimittelresistente Pathogene sein. Die Forschungsarbeiten umfassen die Entwicklung inhalierbarer lumineszierender Partikel, die Methode zur Abgabe des Lichts an die Lunge und die Beurteilung der Behandlungsparameter in entsprechenden klinischen Modellen.
Ziel
Light4lungs addresses the problem of antimicrobial resistance in the treatment of chronic lung infections, which are the leading cause of morbidity and mortality in patients with diseases such as cystic fibrosis and hospital-acquired lung infections. The goal is to develop a novel therapeutic scheme for the treatment of the infections, whereby antibiotics will be replaced by inhalable light sources that will excite bacterial endogenous photosensitisers (e.g. iron-free porphyrins), eliminating the pathogenic bacteria by the photodynamic effect (local production of cytotoxic reactive oxygen species by the combined action of light, a photosensitiser and oxygen) irrespective of its multidrug resistance profile. The treatment will be safe for the host tissue because of its lack of self-photosensitising ability.
Light4Lungs departs from current paradigms: (1) bacterial infections will be treated without antibiotics, which will be replaced by breathable light sources; (2) bacteria will be eliminated without any externally-added drug, taking advantage of endogenous photosensitisers; (3) a breathable light source will be used to elicit the therapeutic action, avoiding the use of invasive physical tethers to deliver light to the lungs. The project encompasses the development of particles with persistent luminescence, the aerosol technology for activation and delivery to the lungs, and the definition of the treatment parameters through toxicity and efficacy tests in clinically relevant models of respiratory infections. The project combines several different scientific expertise from photonics to medicine. The results will be useful for patients with recalcitrant respiratory tract bacterial infections and will eventually be extended to other diseases in the lungs and in other internal organs. The impact reaches beyond antimicrobial resistance itself and will affect many other fields such as healthcare, nanomedicine, materials science and nanotechnology and lightning
Wissenschaftliches Gebiet
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Schlüsselbegriffe
Programm/Programme
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-FETOPEN-2018-2019-2020-01
Finanzierungsplan
RIA - Research and Innovation actionKoordinator
08017 Barcelona
Spanien